» Articles » PMID: 38132285

The Diagnostic Landscape of Adult Neurogenetic Disorders

Overview
Journal Biology (Basel)
Publisher MDPI
Specialty Biology
Date 2023 Dec 22
PMID 38132285
Authors
Affiliations
Soon will be listed here.
Abstract

Neurogenetic diseases affect individuals across the lifespan, but accurate diagnosis remains elusive for many patients. Adults with neurogenetic disorders often undergo a long diagnostic odyssey, with multiple specialist evaluations and countless investigations without a satisfactory diagnostic outcome. Reasons for these diagnostic challenges include: (1) clinical features of neurogenetic syndromes are diverse and under-recognized, particularly those of adult-onset, (2) neurogenetic syndromes may manifest with symptoms that span multiple neurological and medical subspecialties, and (3) a positive family history may not be present or readily apparent. Furthermore, there is a large gap in the understanding of how to apply genetic diagnostic tools in adult patients, as most of the published literature focuses on the pediatric population. Despite these challenges, accurate genetic diagnosis is imperative to provide affected individuals and their families guidance on prognosis, recurrence risk, and, for an increasing number of disorders, offer targeted treatment. Here, we provide a framework for recognizing adult neurogenetic syndromes, describe the current diagnostic approach, and highlight studies using next-generation sequencing in different neurological disease cohorts. We also discuss diagnostic pitfalls, barriers to achieving a definitive diagnosis, and emerging technology that may increase the diagnostic yield of testing.

Citing Articles

Update on Inherited Pediatric Motor Neuron Diseases: Clinical Features and Outcome.

Trabacca A, Ferrante C, Oliva M, Fanizza I, Gallo I, De Rinaldis M Genes (Basel). 2024; 15(10).

PMID: 39457470 PMC: 11507535. DOI: 10.3390/genes15101346.

References
1.
Steffen L, Du R, Gammon A, Mandelblatt J, Kohlmann W, Lee J . Genetic Testing in a Population-Based Sample of Breast and Ovarian Cancer Survivors from the REACH Randomized Trial: Cost Barriers and Moderators of Counseling Mode. Cancer Epidemiol Biomarkers Prev. 2017; 26(12):1772-1780. PMC: 5712253. DOI: 10.1158/1055-9965.EPI-17-0389. View

2.
Bonkowsky J, Nelson C, Kingston J, Filloux F, Mundorff M, Srivastava R . The burden of inherited leukodystrophies in children. Neurology. 2010; 75(8):718-25. PMC: 2931652. DOI: 10.1212/WNL.0b013e3181eee46b. View

3.
Pantera H, Moran J, Hung H, Pak E, Dutra A, Svaren J . Regulation of the neuropathy-associated Pmp22 gene by a distal super-enhancer. Hum Mol Genet. 2018; 27(16):2830-2839. PMC: 6077802. DOI: 10.1093/hmg/ddy191. View

4.
Lin C, Hill C, Kerber K, Burke J, Skolarus L, Esper G . Patient Travel Distance to Neurologist Visits. Neurology. 2023; 101(18):e1807-e1820. PMC: 10634641. DOI: 10.1212/WNL.0000000000207810. View

5.
Srivastava S, Love-Nichols J, Dies K, Ledbetter D, Martin C, Chung W . Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders. Genet Med. 2019; 21(11):2413-2421. PMC: 6831729. DOI: 10.1038/s41436-019-0554-6. View